News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,705 Results
Type
Article (42542)
Company Profile (295)
Press Release (676868)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210474)
Career Advice (2092)
Deals (36634)
Drug Delivery (107)
Drug Development (83066)
Employer Resources (175)
FDA (16586)
Job Trends (15417)
News (356114)
Policy (33933)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51450)
ALS (99)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (140)
Approvals (16583)
Artificial intelligence (280)
Autoimmune disease (24)
Automation (17)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (189)
Bladder cancer (79)
Brain cancer (29)
Breast cancer (293)
Cancer (2356)
Cardiovascular disease (188)
Career advice (1753)
Career pathing (31)
CAR-T (157)
Cell therapy (443)
Cervical cancer (20)
Clinical research (67645)
Collaboration (880)
Company closure (2)
Compensation (572)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (258)
Cystic fibrosis (106)
Data (2338)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6464)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (117)
Drug shortages (28)
Duchenne muscular dystrophy (97)
Earnings (88734)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115540)
Executive appointments (758)
FDA (17986)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (778)
Gene editing (116)
Generative AI (22)
Gene therapy (330)
GLP-1 (760)
Government (4554)
Grass and pollen (5)
Guidances (158)
Healthcare (19004)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (134)
Indications (30)
Infectious disease (2809)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (100)
Interviews (323)
IPO (16803)
IRA (47)
Job creations (4060)
Job search strategy (1492)
Kidney cancer (10)
Labor market (43)
Layoffs (499)
Leadership (18)
Legal (8380)
Liver cancer (77)
Lung cancer (327)
Lymphoma (159)
Machine learning (9)
Management (59)
Manufacturing (340)
MASH (79)
Medical device (13469)
Medtech (13474)
Mergers & acquisitions (20399)
Metabolic disorders (731)
Multiple sclerosis (83)
NASH (17)
Neurodegenerative disease (99)
Neuropsychiatric disorders (29)
Neuroscience (1981)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (40)
Obesity (386)
Opinion (230)
Ovarian cancer (82)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (154)
Partnered (22)
Patents (250)
Patient recruitment (116)
Peanut (49)
People (59328)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (20985)
Phase II (29768)
Phase III (22297)
Pipeline (1381)
Policy (160)
Postmarket research (2654)
Preclinical (8945)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (404)
Real estate (6258)
Recruiting (67)
Regulatory (23194)
Reports (47)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (80)
Series A (134)
Series B (88)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3730)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (55)
The Weekly (50)
Vaccines (720)
Venture capitalists (42)
Weight loss (256)
Women's health (36)
Worklife (16)
Date
Today (184)
Last 7 days (982)
Last 30 days (3152)
Last 365 days (33031)
2025 (12044)
2024 (35771)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40772)
Australia (6529)
California (6442)
Canada (2079)
China (556)
Colorado (277)
Connecticut (281)
Delaware (161)
Europe (87112)
Florida (958)
Georgia (215)
Idaho (57)
Illinois (560)
India (26)
Indiana (331)
Iowa (11)
Japan (175)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (931)
Massachusetts (4828)
Michigan (227)
Minnesota (406)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1808)
New Mexico (29)
New York (1813)
North Carolina (1009)
North Dakota (8)
Northern California (2834)
Ohio (210)
Oklahoma (14)
Oregon (39)
Pennsylvania (1438)
Puerto Rico (13)
Rhode Island (33)
South America (1163)
South Carolina (25)
South Dakota (1)
Southern California (2419)
Tennessee (105)
Texas (960)
United States (24244)
Utah (190)
Virginia (160)
Washington D.C. (64)
Washington State (574)
West Virginia (3)
Wisconsin (59)
719,705 Results for "escient pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.
November 19, 2024
·
2 min read
·
Tristan Manalac
Deals
Incyte Completes Acquisition of Escient Pharmaceuticals
Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.
May 30, 2024
·
5 min read
Deals
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
April 23, 2024
·
8 min read
Deals
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
April 23, 2024
·
2 min read
·
Nick Paul Taylor
Pipeline
Incyte Trims Early-Stage Pipeline Amid Strategic Shift in R&D
Incyte announced Tuesday it is realigning its research and development priorities to focus on dermatology and inflammatory assets obtained from the $750 million acquisition of Escient Pharmaceuticals.
July 31, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD).
November 28, 2023
·
3 min read
Biotech Beach
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.
October 12, 2023
·
3 min read
Biotech Beach
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262 in subjects with chronic inducible urticaria.
September 25, 2023
·
4 min read
Press Releases
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
May 8, 2025
·
5 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
1 of 71,971
Next
